HELENE Clinic, located in Omotesando, Tokyo, Japan, has been dedicated to combining cutting-edge stem cell regenerative medicine with safe, rigorous clinical practices for many years. It provides high-quality, personalized Mesenchymal Stem Cell (MSC) treatments to international clients. The clinic has built an excellent reputation in areas such as anti-aging, overall physical and mental well-being improvement, and cardiovascular risk reduction, earning the trust of many health-conscious customers.
This study was led by the physician team at HELENE Clinic and involved a retrospective analysis of 2,504 patients who received autologous adipose-derived MSC (AD-MSC) intravenous injections at the clinic between 2014 and 2023. The average age of patients was about 54, with a majority being Chinese and Southeast Asian, reflecting the clinic's brand appeal and international influence in the Asian medical beauty and anti-aging medicine market. Notably, over 70% of patients chose MSC treatment primarily for anti-aging purposes, highlighting the clinic's leadership in anti-aging healthcare.
Regarding the dosage distribution, most patients in the study received a relatively high dose of MSC: the average dose was approximately 1.49×10? MSC (nearly 1.5 billion MSC), with a median dose of 2 billion MSC. This means that the majority of patients received very high doses, such as 1–2 billion MSC or even the upper limit of 2 billion MSC. Thus, the study not only evaluated the safety of MSC therapy but also directly verified that MSC treatment remains safe even at such high doses. This finding is particularly compelling for customers who wish to achieve more significant or long-term benefits through high-dose MSC infusions.
The results of the study are encouraging. Over a follow-up period of up to 9 years, the incidence of major adverse cardiovascular and cerebrovascular events (MACCE) among the patients receiving MSC treatment was only 0.2% (5 cases in total), and none were directly related to the MSC treatment, including COVID-19-related pneumonia, accidents, natural elderly death, and stroke. Statistical analysis showed that factors such as gender and MSC dosage had no significant correlation with the risk of MACCE, apart from age. This means that even with high-dose MSC infusions, all patient groups still showed a high level of safety and consistency.
Kaplan–Meier survival curve: shows the status of freedom from major cardiac and cerebrovascular events (MACCE) over time.
The data on adverse reactions are even more reassuring: only 0.8% of patients experienced mild discomfort, such as mild insomnia, temporary changes in menstrual cycles, or slight dizziness. No serious adverse events were reported. These accumulated clinical data clearly demonstrate the safety of MSC treatment itself and further prove that patients' overall tolerance remains good even under high-dose infusions.
Hazard ratio and 95% confidence interval (Cl). Forest plot evaluation ofvariables predicting MACCE-free status in the study population. Error bars represent the95% confidence intervals.**: p-value less than 0.05 was considered statisticallysignificant.
This outcome is of great reference value for consumers seeking to delay aging, improve overall health, and prevent cardiovascular diseases. HELENE Clinic strictly adheres to Good Manufacturing Practices (GMP) for MSC preparation and quality control, customizing the most suitable dosage and treatment plan for each customer. As the study confirms the good safety of high-dose MSC infusions, the clinic can confidently offer high-dose MSC treatments for clients with specific needs, providing a complete service loop—from pre-treatment consultations, MSC injections, rigorous 30-minute monitoring, to post-treatment follow-up via phone or email. This not only showcases the clinic's professional strength and rigorous approach but also solidifies its leadership in the high-end regenerative medicine and anti-aging treatment market.
Compared to traditional healthcare methods, MSC therapy is a regenerative medicine strategy supported by scientific evidence and long-term data. It can help maintain endothelial health, slow down "inflammaging" through immune regulation and tissue regeneration, and ultimately lower cardiovascular risk and improve health in the long term.
Although this study is a retrospective analysis, its large sample size, long follow-up period, and safety verification of high-dose MSC administration lay a solid foundation for subsequent prospective studies. Future research could further explore suitable patient populations using molecular biomarkers and more precisely understand MSC's potential in anti-aging and preventive medicine.
Future directions for research include more stringent age-based subgroup analyses, a deeper exploration of the bioactive factors secreted by MSCs and related molecular mechanisms, and finding the best combined treatment models when integrated with other medical and lifestyle interventions. These studies will assist HELENE Clinic in continuously optimizing MSC treatments to meet the diverse, high-end, and refined health management needs of its clients.
In conclusion, the results of this study show that even at high doses (such as 1 or even 2 billion MSC), AD-MSC intravenous injections at HELENE Clinic provide solid data support in terms of safety and long-term risk management. For customers seeking reliable, professional anti-aging and preventive medicine solutions that balance safety and efficacy with high doses, HELENE Clinic not only represents the rigorous standards and high quality of Japanese healthcare but also paints a promising future and potential for regenerative medicine in the global health management market. Through solid clinical evidence and continuous innovation, HELENE Clinic will continue to lead clients towards a healthier, longer, and higher quality life.
